The effectiveness of Tricine as an adjuvant of cisplatin in the treatment of cutaneous squamous carcinoma is demonstrated using Synchrotron technology
The effectiveness of Tricine as an adjuvant of cisplatin in the treatment of cutaneous squamous carcinoma is demonstrated using Synchrotron technology https://www.tauli.cat/institut/wp-content/uploads/2019/12/IMG_20191216_114446-1200x900.jpg 1080 810 Esperanza Mancebo https://secure.gravatar.com/avatar/8b5e184de8ea8392b071253bfe4ba2fb?s=96&d=mm&r=gDr. Silvia Gil, active member of the cancer research group of I3PT Parc Tauli, has performed in collaboration with researchers at the ALBA Synchrotron Facility a study titled “Multiparametric analysis of the cisplatin effectiveness on cutaneous squamous carcinoma cells by using two different types of adjuvants”.
read more